{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T00:10:51Z","timestamp":1720311051007},"reference-count":22,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["biom rep"],"DOI":"10.3892\/br.2018.1098","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T09:11:16Z","timestamp":1526461876000},"source":"Crossref","is-referenced-by-count":3,"title":["Stevens\u2011Johnsons syndrome or drug\u2011induced lupus \u2011 a clinical dilemma: A case report and review of the literature"],"prefix":"10.3892","author":[{"given":"Violeta","family":"Bojinca","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Sfanta Maria\u2019 Hospital, 011172 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihai","family":"Bojinca","sequence":"additional","affiliation":[{"name":"Clinical Department 5, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madalina","family":"Gheorghe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Sfanta Maria\u2019 Hospital, 011172 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelina","family":"Birceanu","sequence":"additional","affiliation":[{"name":"Clinical Department 5, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Iosif","sequence":"additional","affiliation":[{"name":"Department of Pathology \u2018Sfanta Maria\u2019 Hospital, 011172 Bucharest; 5Department of Cardiology, \u2018Elias\u2019 Hospital, 011461 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serban","family":"Balanescu","sequence":"additional","affiliation":[{"name":"Clinical Department 5, Carol Davila University of Medicine and Pharmacy, 030167 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andra","family":"Balanescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Rheumatology, \u2018Sfanta Maria\u2019 Hospital, 011172 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,5,16]]},"reference":[{"key":"key20200712190042_b1-br-0-0-1098","first-page":"220","article-title":"TNF inhibitors for rheumatoid arthritis - a year in review","volume":"69","author":"Simsek","year":"2011","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"key20200712190042_b2-br-0-0-1098","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/br.2012.42","article-title":"TNF inhibitor therapy for rheumatoid arthritis","volume":"1","author":"Ma","year":"2013","journal-title":"Biomed Rep"},{"key":"key20200712190042_b3-br-0-0-1098","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"key20200712190042_b4-br-0-0-1098","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/BOR.0b013e32835b1366","article-title":"Biologics-induced autoimmune diseases","volume":"25","author":"Perez-Alvarez","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"key20200712190042_b5-br-0-0-1098","first-page":"358","article-title":"Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus","volume":"53","author":"Vaz","year":"2013","journal-title":"Rev Bras Rheumatol"},{"key":"key20200712190042_b6-br-0-0-1098","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: An update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun Rev"},{"key":"key20200712190042_b7-br-0-0-1098","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/MD.0b013e3181441a68","article-title":"Autoimmune diseases induced by TNF-targeted therapies: Analysis of 233 cases","volume":"86","author":"Ramos-Casals","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"key20200712190042_b8-br-0-0-1098","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun Rev"},{"key":"key20200712190042_b9-br-0-0-1098","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/S0025-6196(11)60668-X","article-title":"Lupus-like syndrome attributable to anti-tumor necrosis factor \u03b1 therapy in 14 patients during an 8-year period at Mayo Clinic","volume":"84","author":"Wetter","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"key20200712190042_b10-br-0-0-1098","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.berh.2014.10.001","article-title":"Adverse effects of TNF inhibitors in SpA: Are they different from RA?","volume":"28","author":"Sampaio-Barros","year":"2014","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"key20200712190042_b11-br-0-0-1098","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"J Crohn's Colitis"},{"key":"key20200712190042_b12-br-0-0-1098","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ad.2016.12.014","article-title":"Induction of autoantibodies and autoimmune diseases in patients with psoriasis receiving tumor necrosis factor inhibitors","volume":"108","author":"Oter-L\u00f3pez","year":"2017","journal-title":"Actas Dermosifiliogr"},{"key":"key20200712190042_b13-br-0-0-1098","doi-asserted-by":"publisher","first-page":"10","DOI":"10.12788\/j.sder.0058","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical patterns, diagnostic considerations, etiology, and therapeutic management","volume":"33","author":"Mockenhaupt","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"key20200712190042_b14-br-0-0-1098","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"key20200712190042_b15-br-0-0-1098","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2165\/00128071-200001060-00003","article-title":"Drug-induced Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"1","author":"Fritsch","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"key20200712190042_b16-br-0-0-1098","doi-asserted-by":"publisher","first-page":"R666","DOI":"10.1186\/ar1724","article-title":"Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: A prospective study","volume":"7","author":"Flendrie","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"key20200712190042_b17-br-0-0-1098","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/j.1398-9995.2004.00547.x","article-title":"The lymphocyte transformation test in the diagnosis of drug hypersensitivity","volume":"59","author":"Pichler","year":"2004","journal-title":"Allergy"},{"key":"key20200712190042_b18-br-0-0-1098","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"key20200712190042_b19-br-0-0-1098","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: A severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"key20200712190042_b20-br-0-0-1098","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s12325-017-0530-y","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: A concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures","volume":"34","author":"Schneider","year":"2017","journal-title":"Adv Ther"},{"key":"key20200712190042_b21-br-0-0-1098","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"key20200712190042_b22-br-0-0-1098","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T20:18:53Z","timestamp":1720297133000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2018.1098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,16]]},"references-count":22,"URL":"https:\/\/doi.org\/10.3892\/br.2018.1098","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,16]]}}}